These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32552726)

  • 1. Epidemiology, vaccine effectiveness, and risk factors for mortality for pneumococcal disease among hospitalised adults in Singapore: a case-control study.
    Chan T; Tay MZ; Kyaw WM; Chow A; Ho HJ
    BMC Infect Dis; 2020 Jun; 20(1):423. PubMed ID: 32552726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of invasive pneumococcal disease and vaccine provision in a tertiary referral center.
    Rock C; Sadlier C; Fitzgerald J; Kelleher M; Dowling C; Kelly S; Bergin C
    Eur J Clin Microbiol Infect Dis; 2013 Sep; 32(9):1135-41. PubMed ID: 23525795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive pneumococcal disease and the potential for prevention by vaccination in the United Kingdom.
    Parsons HK; Metcalf SC; Tomlin K; Read RC; Dockrell DH
    J Infect; 2007 May; 54(5):435-8. PubMed ID: 17052760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospital-onset adult invasive pneumococcal disease in Israel: Sicker patients, different pathogens.
    Kenig A; Regev-Yochay G; Khakshoor S; Cohen-Poradosu R; Bishara J; Glikman D; Hershman-Sarafov M; Dagan R; Zimhony O;
    Int J Infect Dis; 2019 Aug; 85():195-202. PubMed ID: 31226404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease.
    Yildirim I; Shea KM; Little BA; Silverio AL; Pelton SI;
    Pediatrics; 2015 Mar; 135(3):495-503. PubMed ID: 25647674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005.
    Harboe ZB; Valentiner-Branth P; Benfield TL; Christensen JJ; Hjuler T; Kaltoft M; Krogfelt KA; Lambertsen L; Konradsen HB
    Vaccine; 2008 Jul; 26(29-30):3765-71. PubMed ID: 18513840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult invasive pneumococcal disease in the Republic of Korea: Risk medical conditions and mortality stratified by age group.
    Kim JH; Baik SH; Chun BC; Song JY; Bae IG; Kim HY; Kim DM; Choi YH; Choi WS; Jo YM; Kwon HH; Jeong HW; Kim YS; Kim JY; Lee J; Kee SY; Hur J; Chung JW; Hwang KE; Kim MJ
    Int J Infect Dis; 2018 Sep; 74():136-144. PubMed ID: 30055332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
    Ingels HA
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.
    Vila-Corcoles A; Ochoa-Gondar O; Guzmán JA; Rodriguez-Blanco T; Salsench E; Fuentes CM;
    BMC Infect Dis; 2010 Mar; 10():73. PubMed ID: 20298596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
    Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
    Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult invasive pneumococcal disease pre- and peri-pneumococcal conjugate vaccine introduction in a tertiary hospital in Singapore.
    Hsu LY; Lui SW; Lee JL; Hedzlyn HMM; Kong DH; Shameen S; Siti NPM; Tan WY; Toh XY; Koh TY; Koh TH
    J Med Microbiol; 2009 Jan; 58(Pt 1):101-104. PubMed ID: 19074659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes.
    Ciruela P; Soldevila N; Hernández S; Selva L; de Sevilla MF; García-García JJ; Moraga F; Planes AM; Muñoz-Almagro C; Domínguez A
    Vaccine; 2013 Jan; 31(6):960-6. PubMed ID: 23261046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Missed opportunities in antipneumococcal vaccination. Can something more be done for prevention?
    Arencibia Jiménez M; Navarro Gracia JF; Delgado de Los Reyes JA; Pérez Torregrosa G; López Parra D; López García P
    Arch Bronconeumol; 2014 Mar; 50(3):93-8. PubMed ID: 24315186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
    Rinta-Kokko H; Palmu AA; Auranen K; Nuorti JP; Toropainen M; Siira L; Virtanen MJ; Nohynek H; Jokinen J
    Vaccine; 2018 Apr; 36(15):1934-1940. PubMed ID: 29526371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].
    Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive pneumococcal disease in Northern Alberta, not a Red Queen but a dark horse.
    Marrie TJ; Tyrrell GJ; Majumdar SR; Eurich DT
    Vaccine; 2018 May; 36(21):2985-2990. PubMed ID: 29685595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
    Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
    Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are current recommendations for pneumococcal vaccination appropriate for Western Australia? The Vaccine Impact Surveillance Network--Invasive Pneumococcal Study Group.
    Med J Aust; 2000 Oct; 173(S2):S36-40. PubMed ID: 11062805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.